IBRX Investors Have Chance to Lead ImmunityBio Securities Fraud Case

In a significant development for investors in ImmunityBio, Inc. (NASDAQ: IBRX), the Rosen Law Firm, a prominent global law firm focusing on investor rights, is encouraging those who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, to consider participating in a securities class action lawsuit. The class action, which aims to hold the company accountable for securities fraud, has set a crucial lead plaintiff deadline of May 26, 2026.

Why This Matters

The lead plaintiff in a class action lawsuit represents the interests of all class members in the case. Investors looking to join the lawsuit are reminded that they can potentially recover compensation without any upfront costs, thanks to a contingency fee arrangement offered by the Rosen Law Firm. This arrangement allows investors to file claims without immediate financial burden, as legal fees are only applicable upon a successful recovery.

Steps for Potential Class Members

If you bought shares in ImmunityBio during the specified Class Period, you may be eligible to be part of this class action. To proceed, individuals can visit the Rosen Law Firm's website or directly contact Phillip Kim, who is leading this particular case. Investors have until May 26, 2026, to apply to serve as lead plaintiff, an important position that entails directing the lawsuit.

The law firm emphasizes the importance of selecting qualified counsel. The Rosen Law Firm prides itself on its history of handling securities litigation effectively and has encouraged investors to avoid less experienced firms. In previous years, the firm has achieved notable settlements in similar cases, including the largest securities class action settlement against a Chinese company.

Allegations Against ImmunityBio

According to the filed lawsuit, several misleading statements were made by the defendants during the Class Period. Notably, allegations state that Patrick Soon-Shiong, a key figure in the company, significantly exaggerated the capabilities of Anktiva, their leading product. As a result, statements regarding ImmunityBio's business operations and future prospects were deemed materially false and lacked any reasonable basis.

When the actual facts emerged, investors reportedly faced substantial financial damages. The lawsuit seeks to redress these grievances by holding the responsible parties accountable for their misleading representations.

Considerations for Investors

While no class has been certified at this point, potential class members have the option to retain their choice of counsel. It’s crucial to understand that joining the class does not limit an investor's recovery options; they can remain absent from the lawsuit if they choose. However, those wishing to take an active role should consider acting promptly to ensure their interests are represented.

To stay updated on developments regarding this case, investors can follow the Rosen Law Firm's official LinkedIn, Twitter, and Facebook pages for real-time news and updates.

As with all investments, there are risks; the current situation emphasizes the importance of being informed and proactive in protecting one's financial interests. For further inquiries, investors are encouraged to reach out to the Rosen Law Firm's representatives who can provide additional guidance and support.

In summary, ImmunityBio, Inc. investors have a pivotal opportunity to join a class action lawsuit that holds the potential for financial recovery in light of serious allegations concerning the company's practices; a timely response will be essential for those looking to assert their rights in this matter.